Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Simplifying Guidelines in Cardio-Kidney-Metabolic Disease
Author(s): Faiez Zannad Added: 1 year ago
Although cardio-kidney-metabolic disease (CKMD) incorporates conditions which share common risk factors, guidelines are often complex and vary between specialist groups. How can we achieve simpler CKMD guidelines to improve implementation?In this short interview, Dr Faiez Zannad (University of Lorraine, Nancy, FR) advocates for a single-set of overarching CKMD guidelines across all specialties… View more

Cardiovascular Kidney Metabolic
Omron logo
Omron Healthcare is a manufacturer of medical equipment for therapy and health monitoring. Our range of products includes blood pressure monitors, portable ECG, augmentation index device, respiratory therapy devices, electronic fever thermometers and body fat monitors among others. Our eco-friendly products are not only known for their high quality and performance standards, but also for their… View more
AHA EPI | Lifestyle 2026
Start date: Mar 17, 2026 End date: Mar 20, 2026
EPI|Lifestyle 2026 is the American Heart Association’s scientific meeting focused on epidemiology, prevention, lifestyle and cardiometabolic health, held from 17–20 March 2026 at the Sheraton Boston, Boston, Massachusetts, USA. The conference brings together population scientists, clinicians and public health professionals to discuss translational and population science, cardiovascular disease … View more

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
Liraglutide Slows Cognitive Decline in Alzheimer's Trial
Added: 6 months ago Source:  Radcliffe CVRM
The glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide did not meet its primary endpoint for changing cerebral glucose metabolism but did show a beneficial effect on a secondary cognitive outcome in patients with mild to moderate Alzheimer's disease (AD), according to results from the phase 2b ELAD trial.¹Liraglutide is a GLP-1 receptor agonist approved for the treatment of type 2… View more

Cardiovascular Kidney Metabolic

Demographic
Eva Gerdts
Research Area(s) / Expertise:

Gender

Hypertension

Obesity

Aortic Disease - General

 Job title: Chief of the Non-invasive Cardiac Imaging Unit
Prof Eva Gerdts is a Professor of Cardiology at the University of Bergen, Norway, andChief of the Non-invasive Cardiac Imaging Unit at theHaukeland University Hospital.She has published more than 240 scientific papers in peer-reviewed journals. Prof Gerdts is a licensed specialist in internal medicine and cardiology in Norway, and graduated from the University of Bergen School of Medicine in 1981… View more
Research Area(s) / Expertise: Job title: Consultant Nephrologist
Dr Andrew Frankel has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease. Over the years he has maintained a significant research interest in relation to diabetes and kidney, both in terms… View more
Fozia Ahmed
Research Area(s) / Expertise: Job title: Consultant Cardiologist (Sub-specialty interests in Heart Failure and Cardiac Devices)
Dr Fozia Ahmed is currently Equality, Diversity and Inclusion lead for the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) and Clinical Research Facility (CRF).She graduated from the University of Manchester in 2003 and undertook specialist training in cardiology in the North-West region. In 2015 she was appointed as a Consultant Cardiologist at… View more
AHA 2025: The TIRZSEMA-CVOT Study
Author(s): Nils Krüger Added: 7 months ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients… View more

Cardiovascular Kidney Metabolic

Heart Failure
Added: 11 months ago Source:  Radcliffe CVRM
Five classic risk factors are responsible for about half of the global cardiovascular disease (CVD) burden. A major new analysis from the Global Cardiovascular Risk Consortium, published in the New England Journal of Medicine, has quantified the profound impact of these factors on lifetime estimates of CVD and all-cause mortality, revealing that their absence at midlife is associated with more… View more

Cardiovascular Kidney Metabolic

Demographic
Job title: Director of the Cardiometabolic Program